COMP360 psilocybin therapy has been designated a breakthrough therapy by the FDA. Take a deep-dive into this revolutionary new therapy, including the therapist training and delivery model and recently reported results from phase IIb clinical trials (COMP 001 and 003) for treatment-resistant depression (TRD). We will also present data from the study at Aquilino Cancer Center of COMP360 psilocybin therapy for patients with cancer and depression that was supported by National Council leadership.
Learning Objectives:
Define treatment resistant depression (TRD) and understand currently available treatment options.
Describe the treatment model of COMP360 psilocybin therapy, including the role of psychological support.
Explain the results of COMP001 for TRD and implications for future research.
Explore the findings of the investigator-initiated study at Aquilino Cancer Center for participants with depression and cancer.
